Valion Bio (VBIO) Preferred Stock Liabilities (2025 - 2026)
Valion Bio (VBIO) posted quarterly Preferred Stock Liabilities of $1.4 million for Q4 2025, down 36.66% quarter-over-quarter from $2.2 million in Q3 2025.
Valion Bio (VBIO) Preferred Stock Liabilities (2025 - 2026) Analysis & Trends
Valion Bio's Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $1.4 million for Q4 2025.
- In Q4 2025, Preferred Stock Liabilities changed N/A year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $1.4 million (changed N/A YoY), while the FY2025 annual figure was $1.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2025 stood at $1.4 million, down from $2.2 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $2.2 million in Q3 2025, with the low at $374000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | - |
| 10 | Valion Bio | 441,427.63 | -1.76 Mn | -45,000.00 | 6.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.22 Mn |
| Dec 31, 2025 | 1.38 Mn |
| Sep 30, 2025 | 2.18 Mn |
| Jun 30, 2025 | 374,000.00 |